19Nov/13

TOPCAT: Spironolactone cuts hospitalizations for diastolic heart failure – Family Practice News Digital Network

TOPCAT: Spironolactone cuts hospitalizations for diastolic heart failure
Family Practice News Digital Network
DALLAS – Spironolactone did not hit a home run in the large international “treatment of preserved cardiac function heart failure with an aldosterone antagonist” (TOPCAT) trial, but it did knock out a solid single in the form of significantly reduced 

19Nov/13

Remission reinduction with rituximab a possibility for ANCA-associated vasculitis – Skin and Allergy News Digital Network

Remission reinduction with rituximab a possibility for ANCA-associated vasculitis
Skin and Allergy News Digital Network
SAN DIEGO – Retreatment of granulomatosis with polyangiitis or microscopic polyangiitis with rituximab may be safe and effective in reinducing remission, a prospective trial has shown. “The vast majority of patients with ANCA [antineutrophil

19Nov/13

Long-Lasting Gene Therapy Benefits Advanced Heart Failure Patients – Science Daily (press release)

Long-Lasting Gene Therapy Benefits Advanced Heart Failure Patients
Science Daily (press release)
19, 2013 — Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the 

and more »

19Nov/13

Janssen Oncology Data to be Presented at 2013 American Society of … – Business Wire (press release)

Janssen Oncology Data to be Presented at 2013 American Society of
Business Wire (press release)
Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852).

and more »